Device Trial Radar · NCT01829997
Assessment of nanOss Bioactive 3D in the Posterolateral Spine
Last checked: Nov 20, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Pioneer Surgical Technology, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 11, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process. nanOss Bioactive 3D is approved for use in the U.S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.
Conditions
- Degenerative Disc Disease
- Spinal Stenosis
- Spondylolisthesis
Interventions
nanOss Bioactive 3D BVFDevice
nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With FusionTime frame: 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital for Joint Disease
New York, New York
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.